Singleron Biotechnologies, a yound and fast growing company developing high-throughput single-cell multiomics platform products with a focus on clinical applications, recently completed Series A2 financing, raising close to $30M. This is the third financing round of the company within four months, following its heavily oversubscribed Series A round in September and Series A1 round in November. Tencent Holdings lead the current A2 round, joined by existing investors Lilly Asia Ventures (LAV), Sherpa Healthcare Partners, CDH Investments, Softbank China Venture Capital, and two other US Dollar funds. Through recent A, A1, and A2 rounds of financing, Singleron has raised about $70M in total and introduced prominent investors such as LAV, CDH, ARCH Venture Partners, CDG Capital, and Tencent as new shareholders of the company.
Founded in 2018, Singleron is dedicated to applying groundbreaking single cell analysis technologies to clinical diagnosis, drug development and health management. The company currently has offices and laboratories in Nanjing, Suzhou, US, and Germany, and provides products and services to about 300 hospitals, research institutes, and pharmaceutical companies. Singleron will invest the proceeds from recent rounds of financing to further develop single-cell platforms and their clinical applications, to accelerate the commercialization of its proprietary technologies, and to ramp up its international presence.
About Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. Its vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.
About Sherpa Healthcare Partners
Sherpa Healthcare Partners was founded in 2018 and has already become an influential healthcare VC firm in the industry. The founders previously worked together in one of China’s leading venture capital firms, built and led its professional medical investment team since 2011, set up the dedicated healthcare investment fund and responsible for healthcare investment. The founders have been teamed together in close co-operation, built on shared values, mutual trust, and complementary capabilities. Based on forward-looking, in-depth industry awareness and extensive networking, Sherpa invest in companies with highly innovative technologies or extraordinary growth potential.
Established in 2002, CDH Investments is one of the leading alternative investment fund managers focused on China today with over US$21 billion of assets under management. CDH has invested in more than 200 companies and has helped more than 70 companies to list successfully on international and China’s domestic stock exchanges. Many of portfolio companies are sector leaders, and, collectively, they play an important role in China’s economy. CDH’s core principle is to create value for all of its partners, including investors and portfolio companies.
Established in 2000, SB China Venture Capital (SBCVC) is a leading venture capital and private equity firm that manages both USD and RMB funds. Its investment focuses on high-tech, high growth companies in TMT, clean technology, healthcare, consumer/retail, and advanced manufacturing sectors; and it invests across all stages of companies.
Phone：+49 221 16824777
E-mail：firstname.lastname@example.org (German office)
Address：Singleron Biotechnologies GmbH, Gottfried-Hagen-Straße 60, 51105 Köln, Germany